fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Mutual Funds » Best Pharma Mutual Funds

Top 4 Best Performing Pharma Mutual Funds 2024

Updated on February 23, 2024 , 202354 views

Pharma Mutual Funds are sector-specific fund that invests in different pharmaceutical companies. Due to the huge population of India, there has always been a high demand for medicines and other health care needs because of which pharma companies have been earning good profits. Read this entire article to know the Indian Pharma sector, it's growth and the best Pharma mutual funds to Invest.

Best Pharma Mutual Fund

Pharma Sector in India

The pharmaceutical sector in India is one of the largest in the world and plays a significant role in the country's Economy. The Industry is known for its low-cost generic drug production and is considered as the "pharmacy of the world." The sector is highly regulated and governed by the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. India has a large number of domestic pharmaceutical companies, as well as several multinational corporations operating in the country. In recent years, the government of India has taken several initiatives to support the growth of the pharmaceutical sector, including tax incentives and investment in research and development.

India has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and about 10,500 Manufacturing units. The industry has been growing rapidly in recent years and has been making significant contributions to the country's economy through exports. According to a report by the Pharmaceuticals Export Promotion Council of India (Pharmexcil), the pharmaceutical exports from India reached around $19 billion in 2020, with the major export markets being the US, Europe, Africa, and Asia.

Largest pharmaceutical companies in India by Market capitalization (as of August 2021) are — Sun Pharmaceutical, Cipla, Lupin, Dr. Reddy’s Labs, Aurobindo Pharma, Divi's Laboratories, Torrent Pharmaceuticals, Glenmark Pharmaceuticals, etc.

If you are keen to invest in the pharma sector fund, the following are the schemes listed for you.

Pharma Equity Funds in India

Pharma funds belong to the equity sectoral fund category which mainly invests in pharma and pharma related stocks. They focus to create a long-term wealth for the investors by taking advantage of growth in the Pharmaceutical sector. In India, some of the top performing funds are - Nippon India Pharma Fund, TATA India Pharma & Healthcare Fund, UTI Healthcare Fund and SBI Healthcare Opportunities Fund.

Nippon India Pharma Fund is in the market since 2004 and has delivered 21.12% returns since inception, whereas UTI Healthcare Fund was launched in 2005 and delivered returns of 18.42% since inception.

SBI Healthcare Opportunities Fund is one of the oldest pharma fund, launched in the year 1999 and has delivered 15.59% returns since its launch.

The category average of pharma funds stood at 131.79% over 1 year period ended 5 March 2010. Three out of four funds have outpaced BSE Healthcare over the same time period. The Reliance India Pharma Fund has topped the category over one year period. The category average has been 19.77% and 18.81% during three years and five years time period.

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Best Pharma Sector Funds 2024

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2023 (%)
TATA India Pharma & Healthcare Fund Growth ₹25.501
↑ 0.13
₹84319.926.459.720.824.636.6
Nippon India Pharma Fund Growth ₹436
↑ 0.91
₹6,89117.824.861.621.424.139.2
UTI Healthcare Fund Growth ₹227.778
↑ 0.65
₹91917.224.658.118.922.738.2
SBI Healthcare Opportunities Fund Growth ₹347.953
↑ 0.65
₹2,43119.224.46221.82538.2
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 23 Feb 24

1. TATA India Pharma & Healthcare Fund

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund was launched on 28 Dec 15. It is a fund with High risk and has given a CAGR/Annualized return of 12.2% since its launch.  Return for 2023 was 36.6% , 2022 was -8% and 2021 was 19.1% .

Below is the key information for TATA India Pharma & Healthcare Fund

TATA India Pharma & Healthcare Fund
Growth
Launch Date 28 Dec 15
NAV (23 Feb 24) ₹25.501 ↑ 0.13   (0.52 %)
Net Assets (Cr) ₹843 on 31 Jan 24
Category Equity - Sectoral
AMC Tata Asset Management Limited
Rating Not Rated
Risk High
Expense Ratio 2.13
Sharpe Ratio 2.1
Information Ratio 0.77
Alpha Ratio 3.61
Min Investment 5,000
Min SIP Investment 150
Exit Load 0-3 Months (0.25%),3 Months and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Jan 19₹10,000
31 Jan 20₹11,015
31 Jan 21₹16,603
31 Jan 22₹19,349
31 Jan 23₹18,651
31 Jan 24₹27,508

TATA India Pharma & Healthcare Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹556,833.
Net Profit of ₹256,833
Invest Now

Returns for TATA India Pharma & Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 23 Feb 24

DurationReturns
1 Month 8.6%
3 Month 19.9%
6 Month 26.4%
1 Year 59.7%
3 Year 20.8%
5 Year 24.6%
10 Year
15 Year
Since launch 12.2%
Historical performance (Yearly) on absolute basis
YearReturns
2023 36.6%
2022 -8%
2021 19.1%
2020 64.4%
2019 5.5%
2018 -2.6%
2017 4.7%
2016 -14.7%
2015
2014
Fund Manager information for TATA India Pharma & Healthcare Fund
NameSinceTenure
Meeta Shetty9 Mar 212.9 Yr.

Data below for TATA India Pharma & Healthcare Fund as on 31 Jan 24

Equity Sector Allocation
SectorValue
Health Care95.65%
Basic Materials2.31%
Asset Allocation
Asset ClassValue
Cash2.03%
Equity97.97%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMA
13%₹96 Cr764,300
Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | LUPIN
11%₹85 Cr643,240
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 30 Apr 20 | AUROPHARMA
9%₹66 Cr611,000
Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | CIPLA
7%₹52 Cr415,000
Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 20 | ALKEM
6%₹43 Cr83,049
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | 500124
6%₹42 Cr72,507
↓ -44,293
Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB
5%₹41 Cr104,965
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Oct 20 | FORTIS
5%₹36 Cr855,100
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSP
4%₹34 Cr58,903
Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Dec 22 | ZYDUSLIFE
4%₹33 Cr478,818

2. Nippon India Pharma Fund

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund was launched on 5 Jun 04. It is a fund with High risk and has given a CAGR/Annualized return of 21.1% since its launch.  Ranked 35 in Sectoral category.  Return for 2023 was 39.2% , 2022 was -9.9% and 2021 was 23.9% .

Below is the key information for Nippon India Pharma Fund

Nippon India Pharma Fund
Growth
Launch Date 5 Jun 04
NAV (23 Feb 24) ₹436 ↑ 0.91   (0.21 %)
Net Assets (Cr) ₹6,891 on 31 Jan 24
Category Equity - Sectoral
AMC Nippon Life Asset Management Ltd.
Rating
Risk High
Expense Ratio 1.97
Sharpe Ratio 2.33
Information Ratio 0.35
Alpha Ratio 2.38
Min Investment 5,000
Min SIP Investment 100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Jan 19₹10,000
31 Jan 20₹10,296
31 Jan 21₹16,065
31 Jan 22₹18,889
31 Jan 23₹18,164
31 Jan 24₹27,476

Nippon India Pharma Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹556,833.
Net Profit of ₹256,833
Invest Now

Returns for Nippon India Pharma Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 23 Feb 24

DurationReturns
1 Month 7.1%
3 Month 17.8%
6 Month 24.8%
1 Year 61.6%
3 Year 21.4%
5 Year 24.1%
10 Year
15 Year
Since launch 21.1%
Historical performance (Yearly) on absolute basis
YearReturns
2023 39.2%
2022 -9.9%
2021 23.9%
2020 66.4%
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%
2014 49.5%
Fund Manager information for Nippon India Pharma Fund
NameSinceTenure
Sailesh Raj Bhan1 Apr 0518.85 Yr.
Kinjal Desai25 May 185.69 Yr.

Data below for Nippon India Pharma Fund as on 31 Jan 24

Equity Sector Allocation
SectorValue
Health Care98.54%
Asset Allocation
Asset ClassValue
Cash1.46%
Equity98.54%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
13%₹826 Cr6,556,349
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | LUPIN
8%₹503 Cr3,803,676
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | CIPLA
6%₹386 Cr3,100,000
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP
6%₹370 Cr648,795
Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND
5%₹327 Cr1,700,000
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | 500124
5%₹319 Cr550,030
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
5%₹293 Cr750,808
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Dec 15 | AUROPHARMA
4%₹249 Cr2,300,800
↓ -199,200
J.B. Chemicals & Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Jan 22 | JBCHEPHARM
4%₹242 Cr1,486,868
Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | 543427
4%₹231 Cr3,076,603

3. UTI Healthcare Fund

(Erstwhile UTI Pharma & Healthcare Fund)

The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.

UTI Healthcare Fund is a Equity - Sectoral fund was launched on 28 Jun 99. It is a fund with High risk and has given a CAGR/Annualized return of 14.8% since its launch.  Ranked 40 in Sectoral category.  Return for 2023 was 38.2% , 2022 was -12.3% and 2021 was 19.1% .

Below is the key information for UTI Healthcare Fund

UTI Healthcare Fund
Growth
Launch Date 28 Jun 99
NAV (23 Feb 24) ₹227.778 ↑ 0.65   (0.29 %)
Net Assets (Cr) ₹919 on 31 Jan 24
Category Equity - Sectoral
AMC UTI Asset Management Company Ltd
Rating
Risk High
Expense Ratio 2.47
Sharpe Ratio 2.26
Information Ratio -0.55
Alpha Ratio 1.59
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Jan 19₹10,000
31 Jan 20₹10,464
31 Jan 21₹16,171
31 Jan 22₹18,756
31 Jan 23₹17,297
31 Jan 24₹25,759

UTI Healthcare Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹530,691.
Net Profit of ₹230,691
Invest Now

Returns for UTI Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 23 Feb 24

DurationReturns
1 Month 7.6%
3 Month 17.2%
6 Month 24.6%
1 Year 58.1%
3 Year 18.9%
5 Year 22.7%
10 Year
15 Year
Since launch 14.8%
Historical performance (Yearly) on absolute basis
YearReturns
2023 38.2%
2022 -12.3%
2021 19.1%
2020 67.4%
2019 1.2%
2018 -7.5%
2017 6.2%
2016 -9.7%
2015 12.4%
2014 43.7%
Fund Manager information for UTI Healthcare Fund
NameSinceTenure
Kamal Gada2 May 221.75 Yr.

Data below for UTI Healthcare Fund as on 31 Jan 24

Equity Sector Allocation
SectorValue
Health Care96.46%
Basic Materials1.42%
Financial Services0.61%
Asset Allocation
Asset ClassValue
Cash1.5%
Equity98.5%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA
13%₹111 Cr880,000
Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | CIPLA
7%₹62 Cr500,000
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP
7%₹61 Cr107,587
↓ -413
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | 500124
7%₹57 Cr98,643
Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | AJANTPHARM
5%₹45 Cr214,336
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Oct 13 | AUROPHARMA
5%₹41 Cr380,000
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | FORTIS
5%₹40 Cr950,000
↓ -65,000
Suven Pharmaceuticals Ltd (Healthcare)
Equity, Since 28 Feb 21 | SUVENPHAR
4%₹32 Cr440,000
↓ -25,000
Krishna Institute of Medical Sciences Ltd (Healthcare)
Equity, Since 30 Jun 21 | 543308
4%₹31 Cr158,483
Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB
3%₹28 Cr70,943
↓ -5,057

4. SBI Healthcare Opportunities Fund

(Erstwhile SBI Pharma Fund)

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy.

SBI Healthcare Opportunities Fund is a Equity - Sectoral fund was launched on 31 Dec 04. It is a fund with High risk and has given a CAGR/Annualized return of 15.5% since its launch.  Ranked 34 in Sectoral category.  Return for 2023 was 38.2% , 2022 was -6% and 2021 was 20.1% .

Below is the key information for SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund
Growth
Launch Date 31 Dec 04
NAV (22 Feb 24) ₹347.953 ↑ 0.65   (0.19 %)
Net Assets (Cr) ₹2,431 on 31 Jan 24
Category Equity - Sectoral
AMC SBI Funds Management Private Limited
Rating
Risk High
Expense Ratio 2.15
Sharpe Ratio 2.32
Information Ratio 0.07
Alpha Ratio 2.79
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-15 Days (0.5%),15 Days and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Jan 19₹10,000
31 Jan 20₹10,386
31 Jan 21₹16,135
31 Jan 22₹18,273
31 Jan 23₹18,393
31 Jan 24₹27,170

SBI Healthcare Opportunities Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹556,833.
Net Profit of ₹256,833
Invest Now

Returns for SBI Healthcare Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 23 Feb 24

DurationReturns
1 Month 8.7%
3 Month 19.2%
6 Month 24.4%
1 Year 62%
3 Year 21.8%
5 Year 25%
10 Year
15 Year
Since launch 15.5%
Historical performance (Yearly) on absolute basis
YearReturns
2023 38.2%
2022 -6%
2021 20.1%
2020 65.8%
2019 -0.5%
2018 -9.9%
2017 2.1%
2016 -14%
2015 27.1%
2014 56.8%
Fund Manager information for SBI Healthcare Opportunities Fund
NameSinceTenure
Tanmaya Desai1 Jun 1112.68 Yr.
Mohit Jain30 Nov 176.17 Yr.

Data below for SBI Healthcare Opportunities Fund as on 31 Jan 24

Equity Sector Allocation
SectorValue
Health Care91.39%
Basic Materials6.68%
Asset Allocation
Asset ClassValue
Cash1.62%
Equity98.07%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA
14%₹313 Cr2,481,262
↑ 81,262
Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | CIPLA
7%₹168 Cr1,350,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
7%₹156 Cr400,000
Aether Industries Ltd (Basic Materials)
Equity, Since 31 May 22 | 543534
5%₹124 Cr1,400,000
Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH
5%₹124 Cr1,800,000
Global Health Ltd (Healthcare)
Equity, Since 31 Oct 22 | MEDANTA
5%₹115 Cr1,200,000
Mankind Pharma Ltd (Healthcare)
Equity, Since 30 Apr 23 | 543904
5%₹111 Cr560,000
Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND
4%₹97 Cr502,296
Rainbow Childrens Medicare Ltd (Healthcare)
Equity, Since 30 Apr 22 | 543524
4%₹95 Cr800,000
Krishna Institute of Medical Sciences Ltd (Healthcare)
Equity, Since 30 Nov 22 | 543308
4%₹95 Cr480,000

Nifty Pharma Index

Generally Pharma Mutual funds follow similar composition of stocks tracking Nifty Pharma Index or CNX Pharma Index as this index is benchmark for Pharma Sector Mutual Funds. Although Pharma Mutual Funds might not necessarily replicate same ratios and components.

Portfolio Characteristics

Portfolio Characteristics
Methodology Periodic Capped Free Float
Launch Date July 01, 2005
Base Date Jan 01, 2001
Base Value 1000
No. of Constituents 20
Calculation Frequency Real Time
Index Rebalancing Semi-Annually

Top Constituents by Weightage

Constituents companies of Nifty Pharma Index with weightage

As on Jan, 2023

Stock Weightage
Sun Pharmaceutical Industries Ltd. 26.88
Cipla Ltd. 13.25
Dr. Reddy's Laboratories Ltd. 12.65
Divi's Laboratories Ltd. 10.17
Lupin Ltd. 4.28
Alkem Laboratories Ltd. 3.55
Torrent Pharmaceuticals Ltd. 3.35
Laurus Labs Ltd. 3.12
Ipca Laboratories Ltd. 2.80
Aurobindo Pharma Ltd. 2.76

To more about index can be read on official website Nifty Pharma Index Document

Who Should Invest in Pharma Mutual Funds?

Being a sector-specific fund, pharma funds carry a huge risk of investment. Investors having an in-depth knowledge of the pharma and healthcare industry are only advised to invest. Also, the ability to bear a high-risk. Investors who think the pharma sector will give good returns in the future or can perform stable in the long-run can invest.

Healthcare Sector in India

1. Public Healthcare

Public healthcare is free for those who are below the poverty line. It encompasses 18% of total outpatient care and 44% of total inpatient care. Middle and upper class individuals tend to use public healthcare less than those with a lower standard of living. Additionally, females and elderly use public services more. The public health care system was originally developed in order to provide a means to healthcare access regardless of socioeconomic status. However, reliance on public and private healthcare sectors varies significantly between states. Several reasons are cited for relying on the private rather than public sector; the main reason at the national level is poor quality of care in the public sector, with more than 57% of households pointing to this as the reason for a preference for private health care.

Most of the public healthcare caters to the rural areas; and the poor quality arises from the reluctance of experienced healthcare providers to visit the rural areas. Consequently, the majority of the public healthcare system catering to the rural and remote areas relies on inexperienced and unmotivated interns who are mandated to spend time in public healthcare clinics as part of their curricular requirement. Other major reasons are distance of the public sector Facility, long wait times, and inconvenient hours of operation.

Different factors related to public healthcare are divided between the state and national government systems in terms of making decisions, as the national government addresses broadly applicable healthcare issues such as overall family welfare and prevention of major diseases, while the state governments Handle aspects such as local hospitals, public health, promotion and sanitation, which differ from state to state based on the particular communities involved. Interaction between the state and national governments does occur for healthcare issues that require larger scale resources or present a concern to the country as a whole.

2. Private healthcare

Since 2005, most of the healthcare capacity added has been in the private sector, or in partnership with the private sector. The private sector consists of 58% of the hospitals in the country, 29% of beds in hospitals, and 81% of doctors. According to National Family Health Survey-3, the private medical sector remains the primary source of health care for 70% of households in urban areas and 63% of households in rural areas. The study conducted by IMS Institute for Healthcare Informatics in 2013, across 12 states in over 14,000 households indicated a steady increase in the usage of private healthcare facilities over the last 25 years for both Out Patient and In Patient services, across rural and urban areas. In terms of healthcare quality in the private sector, a 2012 study by Sanjay Basu et al., published in PLOS Medicine, indicated that health care providers in the private sector were more likely to spend a longer duration with their patients and conduct physical exams as a part of the visit compared to those working in public healthcare.

However, the high out of pocket cost from the private healthcare sector has led many households to incur Catastrophic Health Expenditure, which can be defined as health expenditure that threatens a household's capacity to maintain a basic standard of living. Costs of the private sector are only increasing. One study found that over 35% of poor Indian households incur such expenditure and this reflects the detrimental state in which Indian health care system is at the moment.

With government expenditure on health as a percentage of GDP falling over the years and the rise of private health care sector, the poor are left with fewer options than before to access health care services. Private insurance is available in India, as are various through government-sponsored health insurance schemes. According to the World Bank, about 25% of India's population had some form of health insurance in 2010. 2014 Indian government study found this to be an over-estimate, and claimed that only about 17% of India's population was insured.

How to Invest in Pharma Sector Funds Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.

  2. Complete your Registration and KYC Process

  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest!

    Get Started

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data. Please verify with scheme information document before making any investment.
How helpful was this page ?
Rated 4.4, based on 37 reviews.
POST A COMMENT

Yogesh Kumar Juneja , posted on 5 Sep 21 12:30 PM

Please send list of funds which has the option of changing the sector of funds so that overall performance of mutual funds are always very good. Thanks and Regards

Shailendra, posted on 24 Jul 19 8:02 PM

Are largecap is best investment on longterm

1 - 2 of 2